BridgeBio Oncology Therapeutics, Inc. Notes Payable, Current
BridgeBio Oncology Therapeutics, Inc. (BBOT) had Notes Payable, Current of $716.00 thousand as of 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:NotesPayableCurrent · last filed 2026-05-12
- 2026-03-31: Notes Payable, Current $716.00K.
- 2025-12-31: Notes Payable, Current $534.00K.
- 2025-09-30: Notes Payable, Current $691.00K.
- 2024-12-31: Notes Payable, Current $483.00K.
| Period end | Notes Payable, Current |
|---|---|
| 2026-03-31 | $716.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $534.00K 10-Q · filed 2026-05-12 |
| 2025-09-30 | $691.00K 10-Q · filed 2025-11-12 |
| 2024-12-31 | $483.00K POS AM · filed 2026-04-30 |
| 2023-12-31 | $70.09K 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |